This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Repros' Proellex(R)-V Topline Analysis Suggests 12 Mg Dose Effective And Well Tolerated In Phase 2 For Uterine Fibroids

  • Company to request end of Phase 2 meeting with FDA during Q1 2013
  • Consistent efficacy after 4 months of treatment at 12 mg vaginal dose
  • Overall good benefit risk ratio for 12 mg dose

THE WOODLANDS, Texas, Jan. 3, 2013 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc. ® (Nasdaq:RPRX) today reported top line results from its Phase 2 study of vaginally administered Proellex in the treatment of symptomatic fibroids. The results from the study suggest the 12 mg dose may provide clinical benefit to women suffering from symptomatic uterine fibroids. The Company plans to request an end of Phase 2 meeting with the FDA as soon as practicable.

The primary endpoint in the study was change in Pictorial Blood Loss Assessment (PBAC). Secondary endpoints included change in Uterine Fibroid Symptom Quality of Life (UFSQOL) and change in fibroid volume by MRI assessment.

A total of 40 women were enrolled into the study into one of four groups, 3 mg (n=9), 6 mg (n=9), 12 mg (n=12) and 24 mg (n=10). The following table reports the data from those subjects that completed the study. Unexpectedly, the 24 mg dose exhibited lower exposure than the 12 mg dose which, the Company believes, may result from the hydrophobic nature of the active ingredient and the low volume of excipient used in order to prevent vaginal leakage. Based on these findings, the Company plans to only pursue the 12 mg dose in Phase 3. The MRI report for the 24 mg end of dosing visit is not available at this time but is not expected to be an improvement on the 12 mg dose. In the table, the larger the reduction (negative number), the better the result.

       
Dose (n=subjects completing study) Mean % Change in PBAC (StDev) Mean % Change in UFSQOL (StDev) Mean % Change in Fibroid Volume (StDev)
3 mg (n=8) -58.3 (40.4) -59.3 (41.35) 1 (17.78)
6 mg (n=7) 56.8 (139.3) -6.47 (72.5) -3.1 (20.04)
12 mg (n=11) -84.6 (24.9) -79.1 (31.72) -28.0 (13.3)
24 mg (n=5) -85.5 (20.4) -65 (78.3) Not available

The 12 mg dose exhibited a statistically significant difference (p<0.05) compared to the pooled data from the 3 and 6 mg doses for all three measures. The 6 mg dose group data was affected by a single subject (given the small number of subjects) that exhibited continuous uterine bleeding. This subject also recorded the lone SAE probably associated with administration of the drug following completion of the dosing period. The Company believes this observation was associated with the low level of exposure of the 6 mg dose as well as sporadic (poor compliance) administration of the drug in this individual as exhibited by trough level analysis of the active ingredient at each clinical visit (every two weeks).

1 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,024.06 +183.54 1.03%
S&P 500 2,108.29 +22.78 1.09%
NASDAQ 5,005.3910 +63.9670 1.29%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs